Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0001437749-23-003379 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-14 | 2023-02-10 | PBYI | Ludwig Jeffrey Jerome | Chief Commercial Off | A - Grant | $0.00 | +67.0K | 125.0K | +115% | $0 |
| D | 2023-02-14 | 2023-02-10 | PBYI | Ludwig Jeffrey Jerome | Chief Commercial Off | A - Grant | $0.00 | +93.0K | 93.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | A | A | 66,972 | $0.00 | 125,029 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-10 | A | A | 93,028 | $0.00 | 93,028 | D | $4.39 · — to 2033-02-09 | 93,028 Common Stock | (F2) Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date. |